AstraZeneca Secures $11M+ to Advance a First-in-class Therapy into Phase 2 Clinical Trial for Opioid Use Disorder
$11M
Non-dilutive funding awarded
With more than 89,000 employees and $54 billion in revenue, AstraZeneca is a world leader in bringing new lifesaving innovations to the market. In 2021, the AstraZeneca team initiated development of a new first-in-class therapeutic candidate for the treatment of opioid use disorders (OUDs), and they recognized that a partnership with the NIH would be instrumental in catalyzing the successful product development and launch. However, AstraZeneca was not familiar with the NIH cooperative agreement funding opportunity that supports the development of novel medications for the treatment of OUDs. Therefore, AstraZeneca reached out to EGC for assistance in preparing an NIH proposal.
To support AstraZeneca under an accelerated timeline, EGC assembled a team of Scientific Grants Experts with deep expertise in substance use disorders, drug development, and the targeted NIH grant mechanism. Over the course of eight weeks, EGC supported AstraZeneca in preparing and submitting their NIH application. Within a few months, the NIH signaled its intent to fund the proposal, and EGC supported AstraZeneca through pre-award negotiations. The effort culminated in a four-year, $11 million award.
“It was only with the support of the EGC team that we were able to accomplish this.”
– Nandini Sane, Associate Director, Global Project and Portfolio Management, AstraZeneca
Funding Sources
